Skip to main content
Premium Trial:

Request an Annual Quote

Kevin King, Matthew Robin, Carl Severinghaus, Thomas Bachmann

Affymetrix has named Kevin King as executive vice president and president of its life sciences business, the company said in late December.
King previously worked at Thomson Healthcare, where he oversaw growth and expansion, and he served as vice president and general manager at General Electric Healthcare and he spent 14 years with Hewlett-Packard.

Swiss compounds research company Tecan last month said its board of directors has appointed Matthew Robin and Carl Severinghaus to its group executive committee.
Robin will be responsible for the company’s liquid-handling and robotics business, which is currently being managed by CEO Thomas Bachmann. Robin previously was CEO of medical technology company Ypsomed.


Severinghaus worked previously with Beckman Coulter and the American Monitor Corporation, and has 15 years experience working at Tecan.
In his new position he will manage the company’s direct sales organization.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.